Clik here to view.
Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan...
DUBLIN Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the first patient has been enrolled in a Phase 3 clinical trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of...
View ArticleClik here to view.
The OPTRACT Method: Efficient Human Donor Cornea Transportation Feat ＆...
TOKYO A much efficient human cadaver donor-corneal transportation method, developed by Japanese scientists, may increase the availability of donated eyes to millions of patients with corneal...
View ArticleClik here to view.
Clik here to view.
Clik here to view.
RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular...
TOKYO RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced the results from the investigator sponsored trial (IST), TEMPURA, along...
View ArticleClik here to view.
LENZ Therapeutics and JIXING Announce an Exclusive Greater China License...
SAN DIEGO & SHANGHAI & NEW YORK LENZ Therapeutics (LENZ), a biopharmaceutical company with a lead late clinical-stage program that represents a potential best-in-class therapy for...
View ArticleClik here to view.
iHealthScreen Inc. Announces Australian Health (TGA) Approval for iPredictTM...
NEW YORK iPredictTM AI Eye Screening System provides fully automated diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma suspect screening, including retinal imaging, and...
View ArticleClik here to view.
Santen’s Verkazia® (Cyclosporine Ophthalmic Emulsion) 0.1% Now Available for...
EMERYVILLE, Calif. Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), a global company focused exclusively on eye care, today announced that Verkazia®...
View ArticleClik here to view.
Visus Therapeutics, Inc., and Zhaoke Ophthalmology Limited Announce Exclusive...
SEATTLE & HONG KONG Visus Therapeutics, Inc. (“Visus”), a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the...
View ArticleClik here to view.
Lumenis OptiLight荣获2022年MedTech Breakthrough奖：眼科最佳新技术解决方案
以色列约克尼穆 (美国商业资讯)–领先的能量型美容和眼科医疗设备公司Lumenis Be.今天宣布，OptiLight荣获竞争激烈的MedTech...
View ArticleClik here to view.
ルミナスのOptiLightが2022年メドテック・ブレークスルー賞の「最優秀眼科用新技術ソリューション」部門を受賞
イスラエル・ヨクネアムイリト （ビジネスワイヤ） —...
View ArticleClik here to view.
OliX Pharmaceuticals to Conduct Business Meetings with Potential Partners at...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company’s management will participate in one-on-one partnering...
View ArticleClik here to view.
OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology...
SUWON, South Korea OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for...
View ArticleClik here to view.
Seoul Semiconductor: The #1 in Patent Power Pre-empting the Future with 2nd...
ANSAN, South Korea Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a global optical semiconductor company, announced that Seoul Semiconductor and Seoul Viosys (hereafter referred to as Seoul) are...
View ArticleClik here to view.
ナンバーワンの特許力を持つソウル半導体が、第2世代LED技術で未来を先取り
韓国安山市 (ビジネスワイヤ) — 光半導体の世界的企業であるSeoul Semiconductor Co., Ltd.（KOSDAQ：046890、本社：韓国安山市、代表理事：李貞勲、以下「ソウル半導体」）は、ソウル半導体とソウルバイオシス（以下、総称して「ソウル」）が韓国第1位の光半導体（LED）企業であり、世界第1位の特許力を持つ企業の1つであると発表しました。...
View ArticleClik here to view.
Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in...
SEATTLE Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the...
View ArticleClik here to view.
Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement...
KANAGAWA, Japan & LITTLE ROCK, Ark. Kuria Therapeutics, Inc., a US pharmaceutical company developing novel therapeutics for ophthalmic and dermal diseases, and SCOHIA PHARMA, Inc, a Japanese...
View ArticleClik here to view.
OliX Pharmaceuticals Announces IND Submission to U.S. FDA to Evaluate Safety...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced the submission of an Investigational New Drug (IND) application to the US...
View ArticleClik here to view.
Dr. Reddy’s Laboratories enters into a licensing agreement with Slayback...
HYDERABAD, India & PRINCETON, N.J. Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today...
View ArticleClik here to view.
OliX Pharmaceuticals Receives IND Approval from FDA to Develop RNAi...
SUWON, South Korea OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s...
View Article